3,4,3'-Tri--methylellagic acid as an anticancer agent: and studies.

We report a natural product compound isolated from known as 3,4,3'-tri--methylellagic acid (T-EA) as a candidate drug for cancer treatment. The characterization of the isolated T-EA compound was carried out using various spectroscopic methods. The evaluation showcased the inhibition activity of T-EA towards the T47D and HeLa cell lines with EC values of 55.35 ± 6.28 μg mL and 12.57 ± 2.22 μg mL, respectively. Meanwhile, the evaluation aimed to understand the interaction of T-EA with enzymes responsible for cancer regulation at the molecular level by targeting the hindrance of cyclin-dependent kinase 9 (CDK9) and sirtuin 1 (SIRT1) enzymes. T-EA showed a binding free energy towards the SIRT1 protein of Δ : -30.98 ± 0.25 kcal mol and Δ : -24.07 ± 0.30 kcal mol, while that of CDK9 was Δ : -29.50 ± 0.22 kcal mol and Δ : -25.87 ± 0.40 kcal mol. The obtained results from this research could be considered as important information on 3,4,3'-tri--methylellagic acid as a drug to treat cervical and breast cancers.